The Opportunity

Zystor is a new therapeutic to treat Lysosomal Storage Diseases, a group of forty rare diseases that are each caused by a different missing lysosomal enzyme.

How We Helped

Venture Investors served as co-lead investor and helped build the syndicate for the creation of Zystor when it simultaneously acquired the assets of Symbiontics Corp of St. Louis, forming a new biotechnology company located in Milwaukee, Wisconsin. The structure of the transaction was designed to facilitate continuity in the research and development program, while forming a new legal entity based in Wisconsin to allow for participation from state-focused investors in the syndicate.


Zystor was acquired by BioMarin for up to $115 million.